Gregory Perry

Gregory D.
Perry is currently Director at Oculis Holding AG since 2026 and Chief Financial Officer at Merus NV since 2023.
Formerly, served as Independent Director at Kala Bio, Inc. from 2018 to 2025; Chief Financial Officer at Finch Therapeutics Group, Inc. from 2018 to 2022; Chief Financial & Administrative Officer at Novelion Therapeutics, Inc. in 2017; Chief Financial & Administrative Officer at Aegerion Pharmaceuticals, Inc. in 2016; Independent Director at Astellas Institute for Regenerative Medicine from 2012 to 2016; Chief Financial & Business Officer at Sesen Bio, Inc. from 2014 to 2015; Director at rEVO Biologics, Inc. in 2014; Chief Financial Officer at Invivo Therapeutics Holdings Corp.
in 2013; Chief Financial Officer, Treasurer & Executive VP at ImmunoGen, Inc. from 2011 to 2013; Chief Financial Officer & Executive Vice President at Elixir Pharmaceuticals, Inc. from 2007 to 2008; Chief Financial Officer at Domantis Ltd. in 2006; Chief Financial Officer & Senior Vice President at Transkaryotic Therapies, Inc. from 2003 to 2005; SVP-Finance, Business Development & Life Sciences at Revvity, Inc.; and Chief Financial Officer & Vice President at GE Medical Systems, Inc. Education includes undergraduate degree from Amherst College.